Bi Specifics in Diffuse Large B Cells?

With the approval of mousinutuzumab also to close the map in myeloma. And as you're saying, a couple here on Gvisar's BSA, likely to come into practice. Of course, the general medical oncologist is asking, are we going to be able to give these drugs? I'm curious, first of all, in a way it's hard,  to separate out how complicated it is to give one versus the other. They all cause CR, you know, it's kind of like they all come together,. Even to clistumab. You have really to show benefit with antibody drug conjugate. Obviously there are